Medplus's Subsidiary Receives Drug License Suspensions in Andhra Pradesh and Telangana
Medplus Health Services Limited announced that its subsidiary, Optival Health Solutions Private Limited, has received two separate suspension orders for Drug Licenses concerning stores in different locations.The suspension orders were received on April 19, 2026, from drug control administrations in Andhra Pradesh and Telangana. These actions are based on alleged contraventions under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.
The impact and details of the suspensions are presented in the following table:
| Authority Name | Nature of Action | Date of Order Receipt | Violation Details | Financial Impact |
|---|---|---|---|---|
| Assistant Director and sales licensing authority, Drug control administration, Kurnool, Andhra Pradesh | Suspension of Drug License for seven days of store situated at Kodumur New Bus Stand, Andhra Pradesh. | 19.04.2026 | Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 | Potential Revenue Loss of Rs 0.88 lacs. |
| Assistant Director, Drugs Control Administration, Nalgonda, Telangana | Suspension of Drug License for two days of store situated at Miryalaguda Road Bottu Guda, Telangana. | 19.04.2026 | Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 | Potential Revenue Loss of Rs 0.37 lacs. |
The total potential revenue loss associated with these suspensions is calculated based on the individual reported figures.
MEDPLUS Stock Price Movement
Medplus Health Services Limited shares today slipped by 1.27% to settle at ₹869.8 in post-market trading. The stock saw a trading volume of 45,129 shares during the session.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.